Abbreviations:
SARS-CoV-2 infection, respiratory syndrome, Sonoyama T
CORONAVIRUS, INFECTIOUS DISEASES, SARS-COV-2 INFECTION
3C-likeadverse eventconfidence intervalcoronavirus disease 2019cytochrome P450 3Afood and drug administrationelectronic case report formintention-to-treatmodified intention-to-treatribonucleic acidreverse transcription-polymerase chain reactionserious adverse eventsevere acute respiratory syndrome coronavirus 2World Health OrganizationProtocol version: Version 10, Amendment 9, Issued 20 September 2022. Publication history: This manuscript was previously posted to Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.This study was funded by Shionogi & Co., Ltd., and financially supported by the Organization of the Ministry of Health, Labor and Welfare. Employees of Shionogi & Co., Ltd., participated in and approved the design and conduct of the study, wrote the protocol, and were involved in the collection, management, analysis, and interpretation of data. Institutional authors reviewed and approved the protocol and collected and interpreted the data.Supplemental Digital Content is available for this article.HY reports consulting fees from Shionogi, lecture fees from Shionogi and ViiV Healthcare, and travel support from Shionogi outside the submitted work. He serves as an advisory board member for Shionogi and President of the Japanese Society of Infectious Diseases. NO declares no conflict of interest. YD reports grants from Shionogi and Entasis; consulting fees from Shionogi, Meiji Seika Pharma, Gilead Sciences, GSK, MSD, Chugai, and bioMerieux; and lecture fees from MSD, AstraZeneca, Shionogi, and Teijin Healthcare outside the submitted work and serves as an advisory board member for FujiFilm. TI, T Sonoyama, GI, T Sanaki, YT, and TU are full-time employees of Shionogi & Co., Ltd., and may own stocks or stock options. HM has received funding relevant to the submitted work from Shionogi and grants from Taisho Pharma; lecture fees from Pfizer, MSD, Shionogi, and Taisho Pharma; and advisory fees from Pfizer, MSD, and Shionogi outside the submitted work.Trial sponsor: Shionogi & Co., Ltd.Trial registration: Japan Registry of Clinical Trials (How to cite this article: Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part). Medicine 2023;102:8(e33024).